Eureka Therapeutics
Developing novel T-cell therapies that harness the evolutionary power of the immune system with the goal of curing cancer
Partners
Strategic alliances bringing more cancer solutions to patients
Our Science and Technology
Potentially safer and more efficient T-cell immunotherapies against solid and hematological tumors

About Us

Eureka Therapeutics is a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system with the goal of curing cancer.

Recent News

Renowned physician-scientist, David A. Scheinberg, MD, PhD, to join Scientific Advisory Board of Eureka Therapeutics

Our Science and Technology

Faster and safer immunotherapies that defeat cancer cells while minimizing side effects

Pipeline

Our pipeline encompasses T cell therapies targeting well-studied cancer specific antigens, e.g. testis antigens, mutated oncogenes, viral antigens. Our lead program for liver cancer, ET1402, is expected to enter Phase I in 2017.

Partnerships

Collaborations are a vital pillar of our strategy for developing first-in-class immunotherapy for solid tumors. We believe that collaboration is key to achieving a “cure for cancer.” We welcome partnership opportunities around our technology platforms and product pipeline.

Upcoming Events

There are no upcoming events at this time.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.